What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD-Reference-Cited by-同舟云学术

What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD

Published:2020-01-09 Issue:4 Volume:19 Page:370-387
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceutical Statistics

Author:

Keene Oliver N.¹^ORCID,Ruberg Stephen²,Schacht Alexander³,Akacha Mouna⁴,Lawrance Rachael⁵,Berglind Anna⁶,Wright David⁷

Affiliation:

1. GlaxoSmithKline Stockley Park UK

2. Analytix ThinkingLLC Indianapolis Indiana USA

3. Lilly Deutschland Bad Homburg Germany

4. Novartis Pharma AG Basel Switzerland

5. Adelphi Values Bollington UK

6. AstraZeneca Gothenburg Sweden

7. AstraZeneca Cambridge UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.1986

Reference29 articles.

1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials Step 2b. London: European Medicines Evaluation Agency August2017.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/08/WC500233916.pdf(accessed August 9 2019)

2. Committee for Human Medicinal Products. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus.https://www.ema.europa.eu/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus_en.pdf(accessed August 9 2019)

3. Committee for Human Medicinal Products. Guideline on the clinical investigation of medicines for the treatment of Alzheimer's disease.https://www.ema.europa.eu/documents/scientific‐guideline/guideline‐clinical‐investigation‐medicines‐treatment‐alzheimers‐disease‐revision‐2_en.pdf(accessed August 9 2019)

4. Prioritised research agenda for prevention and control of chronic respiratory diseases

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Duration of and time to response in oncology clinical trials from the perspective of the estimand framework;Pharmaceutical Statistics;2023-10-02

2. Application of Bayesian approaches in drug development: starting a virtuous cycle;Nature Reviews Drug Discovery;2023-02-15

3. Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?;Value in Health;2023-02

4. Estimands in heath technology assessment: a causal inference perspective;Statistics in Medicine;2022-11-17

5. Development of a Definition for Medical Affairs Using the Jandhyala Method for Observing Consensus Opinion Among Medical Affairs Pharmaceutical Physicians;Frontiers in Pharmacology;2022-02-22